Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2020 | Large networks in CLL research

Ulrich Jäger • 7 Oct 2020
ERIC 2020
Chronic Lymphocytic Leukemia Leukemia

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the generation of large networks that influence research. For example, the Innovative Medicines Initiative (IMI) HARMONY Project and the Horizon Europe program. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.

More from Ulrich Jäger

The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies 1:23
The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
Ulrich Jäger • 7 Feb 2025
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia 1:32
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
Ulrich Jäger • 7 Feb 2025
Working towards the harmonization of CAR-T registries 1:17
Working towards the harmonization of CAR-T registries
Ulrich Jäger • 7 Feb 2025
The potential role of the tumor microenvironment in CAR T-cell therapy 0:52
The potential role of the tumor microenvironment in CAR T-cell therapy
Ulrich Jäger • 7 Feb 2025

Related Videos

HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML 8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
POD36 as a prognostic marker and clinical tool in frontline CLL 3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology 7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
Recent advancements in the understanding of Richter’s transformation 1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals